RMD · XBRL financial data

ResMed financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (RMD's year ends in late June)

In millions of dollars	FY 2021Jun 30, 2021	FY 2022†Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Revenue from contracts with customers	3,197	3,578	4,223	4,685	5,146	5,653
Cost of goods and services sold	1,358	1,554	1,867	2,030	2,091	2,202
Gross profit	1,839	2,024	2,356	2,655	3,055	3,452
Research and development	225	254	288	308	331	378
Selling, general and administrative	670	739	874	917	991	1,120
Total operating expenses	935	1,024	1,224	1,335	1,370	1,565
Operating income (loss)	904	1,000	1,132	1,320	1,685	1,887
Interest income	0	—	—	—	—	—
Interest expense	24	—	—	—	—	—
Other income (expense)	15	3	(6)	(3)	(5)	(9)
Income tax expense (benefit)	409	181	204	244	277	396
Net income (loss)	475	779	898	1,021	1,401	1,523
Earnings per share, basic USD per share	3.27	5.34	6.12	6.94	9.55	10.47
Earnings per share, diluted USD per share	3.24	5.30	6.09	6.92	9.51	10.43
Weighted average shares, basic millions of shares	145	146	147	147	147	146
Weighted average shares, diluted millions of shares	146	147	147	148	147	146

† Share count changed about 1005x in the period ending 2022-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (RMD's year ends in late June)

In millions of dollars	FY 2021Jun 30, 2021	FY 2022†Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Cash and cash equivalents	295	274	228	238	1,209	1,469
Accounts receivable	614	576	705	837	939	1,036
Inventory	457	744	998	822	928	946
Prepaid and other current assets	136	338	437	460	429	416
Total current assets	1,575	1,931	2,368	2,358	3,506	4,325
Property and equipment, net	463	498	538	548	551	582
Right-of-use asset	129	132	128	151	167	153
Goodwill	1,928	1,936	2,770	2,842	3,047	2,910
Total assets	4,728	5,096	6,752	6,872	8,174	8,966
Accounts payable	138	159	151	238	278	309
Accrued liabilities	321	345	366	378	402	495
Total current liabilities	912	689	759	911	1,019	1,395
Lease liability, non-current	115	120	117	141	153	137
Total liabilities	1,842	1,735	2,622	2,008	2,207	2,381
Retained earnings	3,080	3,614	4,253	4,992	6,081	7,255
Total stockholders' equity	2,886	3,361	4,130	4,864	5,968	6,585
Total liabilities and equity	4,728	5,096	6,752	6,872	8,174	8,966
Common shares outstanding (cover page) millions of shares	0	146	147	147	146	144

† Share count changed about 1005x in the period ending 2022-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (RMD's year ends in late June)

In millions of dollars	FY 2021Jun 30, 2021	FY 2022†Jun 30, 2022	FY 2023Jun 30, 2023	FY 2024Jun 30, 2024	FY 2025Jun 30, 2025	FY 2026Jun 30, 2026
Net income (loss)	475	779	898	1,021	1,401	1,523
Stock-based compensation	64	65	71	80	92	104
Depreciation and amortization	157	160	165	177	198	201
Net cash from operating activities	737	351	693	1,401	1,752	1,806
Purchases of property and equipment	103	135	120	99	90	156
Net cash from investing activities	(158)	(230)	(1,160)	(270)	(200)	(545)
Proceeds from issuing common stock	38	47	49	53	74	75
Share repurchases	—	0	0	150	300	700
Dividends paid	227	245	258	282	311	350
Proceeds from long-term debt	90	288	1,070	105	0	0
Repayments of long-term debt	612	166	405	835	40	10
Net cash from financing activities	(765)	(128)	423	(1,119)	(606)	(1,007)
Net change in cash	(168)	(22)	(46)	10	971	260

† Share count changed about 1005x in the period ending 2022-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Resmed	1,011	1,415	422	140.7M	—	Q1 FY27 10-QSep 30, 2026
Dexcom	961	1,345	326*	373.0M	—	Q3 FY26 10-QSep 30, 2026
GE HealthCare Technologies	2,826	5,513	907*	452.1M	—	Q3 FY26 10-QSep 30, 2026
Edwards Lifesciences	2,907	1,741	652*	576.4M	—	Q2 FY26 10-QJun 30, 2026
STERIS	482	1,493	367	97.5M	—	Q1 FY27 10-QJun 30, 2026
Insulet	535	802	88*	69.4M	—	Q2 FY26 10-QJun 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
Becton Dickinson	708	4,983	not reported	272.4M	—	Q3 FY26 10-QJun 30, 2026
Zimmer Biomet Holdings	410	2,177	448*	190.7M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.